Brief: Abbisko Cayman Says CDE Of NMPA Clears Ind For Abbisko's Pd-L1 Inhibitor Combo For NSCLC
20/08/2025 15:57
Aug 20 (Reuters) - Abbisko Cayman Ltd 2256.HK: CDE OF NMPA CLEARS IND FOR ABBISKO'S PD-L1 INHIBITOR COMBO FOR NSCLC Further company coverage: 2256.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly